芳香化酶抑制剂相关骨关节疼痛的影响因素分析

Influence factors of aromatase inhibitor-related arthralgia

目的:探讨乳腺癌患者服用芳香化酶抑制剂(AIs)治疗过程中产生不良反应骨关节疼痛(AIA)的影响因素,提高对AIA的认识,以利于改善AIs用药依从性。方法:采用回顾性研究方法,纳入采用AIs辅助治疗的乳腺癌患者105例,应用卡方检验及二元Logistic回归进行AIA相关风险因素评估;应用卡方或Fisher精确检验进行疼痛程度与独立影响因素的相关性分析。结果:105例患者中49.5%出现了AIA症状,其中约83%在开始服药后6个月内发生。统计学分析显示:年龄<55岁、Her-2阴性、未服用碳酸钙D3,与发生AIA有显著意义且为独立影响因素(P<0.05);未服用碳酸钙D3与高疼痛评分相关(P<0.05)。结论:年龄<55岁,Her-2阴性、未服用碳酸钙D3的患者AIA的发生率高;服用碳酸钙D3可降低疼痛评分。

Objective： To identify the risk factors of aromatase inhibitor （AI）-related arthralgia （AIA） for predicting the risk of AIA and improving compliance of medication. Methods： A total of 105 breast cancer patients with AI monotherapy were reviewed. We evaluated the potential clinical factors for AIA using chi-square test and the multivariate logistic regression model. We evaluated the correlation between the pain score and independent factors using the chi-square or Fisher＇s exact test. Results： Among 105 patients, 49.5% patients experienced AIA symptoms. Approximately 83% patients reported AIA within the first 6 months. Statistical analysis demonstrate that age 〈55y, Her-2 negative and not taking calcium D3 were significant and independent associated factors to AIA （P 〈 0.05）. Not taking calcium D3 was correlated with the high degree of pain score （P 〈 0.05 ）. Conclusion ： Age 〈 55 years, Her-2 negative and not taking calcium D3 are associated with the high incidence of AIA in breast cancer patients. Use of calcium D3 could reduce pain scores.